Nanoparticle-Aptamer Bioconjugates

By O. Farokhzad, S. Jon, Ali Khademhosseini, T. Tran, David A Lavan, Robert Langer. Cancer Research, 2004

619 citations recorded by the source corpus.

Subfields: Molecular Biology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/fe12a66b44ea99f1968b56db06a4f32c21ea3ae5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. N. Bertrand
2. N. Kamaly
3. Xiaoyang Xu
4. Jun Wu
5. O. Farokhzad
6. I. Rubinstein
7. O. Koo
8. T. Jacks

In Radiology, Nuclear Medicine and Imaging

1. N. Bertrand

Citations in the corpus

• Treating metastatic cancer with nanotechnology (2011, background): “, such as antibodies, peptides and nucleic acid-based ligands ( aptamers”
• Role of nanotechnology in targeted drug delivery and imaging: a concise review. (2005, background): “NGR peptide Aminopeptidase N (CD13) Liposomes [43] NGF peptide Tyrosine kinase A (TrkA) receptors Quantum dots [205] Gelatinase inhibitory peptide CTTHWGFTLC MMP-2 and MMP-9 gelatinase Liposomes and albumin nanoparticles [42] Aptamers Proteins, peptides, enzymes, antibodies, various cell surface rec”
• Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014, background): “In vitro feasibility of Apt-decorated NPs to target the prostatespecific membrane antigen (PSMA) cancer marker was reported in 2004 [286].”